![Intellia Therapeutics, Inc. logo](/logos/NTLA.webp)
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Overview | Financials
Company Name | Intellia Therapeutics, Inc. |
Symbol | NTLA |
Currency | USD |
Price | 26.5 |
Market Cap | 2,556,598,100 |
Dividend Yield | 0% |
52-week-range | 19.37 - 43.06 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. John M. Leonard M.D. |
Website | https://www.intelliatx.com |
An error occurred while fetching data.
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD